Maraviroc - Open Access .click

Results 71 to 80 of about 7,321 (205)

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis

AIDS Research and Therapy, 2020
Background Entry inhibitors, such as Maraviroc, hold promise as components of HIV treatment and/or pre-exposure prophylaxis in Africa. Maraviroc inhibits the interaction between HIV Envelope gp120 V3-loop and CCR5 coreceptor. HIV-1 subtype C (HIV-1-C) is
Nontokozo D. Matume, Denis M. Tebit, Pascal O. Bessong +2 more
doaj +1 more source

A Proof‐of‐Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non‐Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis

Liver International Communications, Volume 6, Issue 4, December 2025.
ABSTRACT Chemokine receptor type 5 (CCR5) is upregulated in the livers of patients with metabolic dysfunction–associated steatohepatitis (MASH). Leronlimab, a humanised IgG4κ monoclonal antibody, directly binds the extracellular domains of CCR5, modulates downstream signalling and potentially can slow, reverse or prevent fibrosis. The aim of this study
Melissa Palmer +10 more
wiley +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena +8 more
doaj +1 more source

Abatacept Prevents Severe Acute Graft‐Versus‐Host Disease Without Increasing Graft Failure Risk in Pediatric Bone Marrow Failure Syndromes

Pediatric Blood &Cancer, Volume 72, Issue 12, December 2025.
ABSTRACT Background Pediatric patients with inherited or acquired bone marrow failure syndromes (BMFS) often require an allogeneic hematopoietic stem cell transplant (HSCT) to cure the hematological manifestations. Amongst these, those without a matched sibling donor (MSD), are at increased risk for graft failure and are known to tolerate graft‐versus ...
Zahra Hudda +7 more
wiley +1 more source

Spatial transcriptomics in epilepsy research: Early successes, opportunities, and challenges

Epilepsia, Volume 67, Issue 4, Page 1589-1600, April 2026.
Donald J. Phillips +4 more
wiley +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +206 more
wiley +1 more source

Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile^®

Viruses
HIV-1 typically infects cells via the CD4 receptor and CCR5 or CXCR4 co-receptors. Maraviroc is a CCR5-specific viral entry inhibitor; knowledge of viral co-receptor specificity is important prior to usage. We developed and validated an economical V3-env
Daisy Ko +7 more
doaj +1 more source

Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.

PLoS ONE, 2013
Maraviroc, an (HIV-1) entry inhibitor, binds to CCR5 and efficiently prevents R5 human immunodeficiency virus type 1 (HIV-1) from using CCR5 as a coreceptor for entry into CD4(+) cells.
Yuzhe Yuan +6 more
doaj +1 more source

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.

PLoS ONE, 2013
BackgroundDual/mixed-tropic HIV-1 strains are predominant in a significant proportion of patients, though little information is available regarding their replication-capacity and susceptibility against CCR5-antagonists in-vitro.
Matteo Surdo +11 more
doaj +1 more source

An LCN2‐Dependent Positive‐Feedback Loop Between Gastric Cancer Cells and Tumor‐Associated‐Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis

Advanced Science, Volume 12, Issue 44, November 27, 2025.
In this study, the expression and function of LCN2 in GC is aimed to investigate and elucidate the mechanisms by which the LCN2‐dependent positive‐feedback loop between GC cells and TAMs drives lymphangiogenesis and lymphatic metastasis. These findings suggest that LCN2 may serve as a potential prognostic biomarker and therapeutic target in GC ...
Zhixin Huang +15 more
wiley +1 more source

medicine
3. good health
cyclohexanes

humans
triazoles
hiv infections

hiv-1
hiv fusion inhibitors
anti-hiv agents